CereVasc, Inc. Completes Enrollment in STRIDE Pivotal Trial of the eShunt® System
Advancing Toward FDA Premarket Approval (PMA) for a Minimally Invasive Treatment of Normal Pressure Hydrocephalus STRIDE is the first and largest randomized, controlled trial conducted comparing a minimally invasive alternative to the standard-of-care ventriculo-peritoneal (VP) shunt, a...
Advancing Toward FDA Premarket Approval (PMA) for a Minimally Invasive Treatment of Normal Pressure Hydrocephalus STRIDE is the first and largest randomized, controlled trial conducted comparing a minimally invasive alternative to the standard-of-care ventriculo-peritoneal (VP) shunt, a...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.